Drug Profile

AGEN 1223

Alternative Names: AGEN-1223

Latest Information Update: 23 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Agenus
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

23 Mar 2023 3768152 - Deal updated, Deal termination HE added
31 Oct 2021 Gilead Sciences terminates license agreement with Agenus for AGEN 1223
29 Sep 2021 Agenus terminated the phase I trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral) due to strategic business decision (NCT04156100)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com